Treating circulatory failure: a delicate balance [Session]

The first afternoon session dives deep into some of neonatology's most enduring debates: managing the PDA and navigating the extreme pharmacological complexities of vasoactive drugs in premature infants.

Here is a breakdown of the core messages from each speaker:

• Pharmacological Management of PDA (Gilles Cambonie)

  • The debate over managing presymptomatic PDAs in extreme preterms continues. Prophylactic or early routine pharmacological treatment (within the first two weeks) is generally not recommended, as studies show it does not improve long-term outcomes (mortality or severe neurodevelopmental disability) and may increase risks of adverse events like severe BPD or infections.

  • However, for symptomatic cases or those failing conservative management, targeted pharmacological closure remains a reasonable approach.

  • Future research must focus on the most vulnerable subgroups (≤26 weeks) possibly using AI, multimodal physiologic monitoring, and targeted biomarkers to identify the precise window for intervention.

• Long-Term Outcomes: Expectant vs. Active PDA Management (Ilhaam Ouamari)

  • A comprehensive systematic review and meta-analysis found no statistically significant difference in survival without neurodevelopmental impairment (NDI) between expectant management and active treatment groups overall.

  • Interestingly, a small subgroup analysis of studies with follow-ups beyond two years suggested active treatment might favor survival without NDI, potentially linked to a reduction in severe IVH when prophylaxis was used in older trials.

  • However, the data quality is limited by high heterogeneity and short follow-up periods. There is an urgent need for PDA trials to track outcomes well into school age to see if children "grow into a deficit."

• Dynamic Dosing of Vasoactive Drugs (Vincenzo Cannizzaro)

  • Traditional adult-based pharmacology fails in neonates. Blood pressure changes cannot be reliably attributed to a single drug-receptor interaction, and traditional alpha/beta receptor targeting is overly simplistic for clinical shock.

  • The Delivery Delay: The programmed pump rate does not equal immediate drug delivery. With tiny infusion volumes and significant dead space, changing the delivery time can take minutes to several hours depending on the infusion configuration. The drug might not even be reaching the baby when you are expecting a clinical response.

  • Dynamic Dosing: Dosing must move away from linear escalation. It requires understanding the specific physiological problem and continuously reassessing the response before arbitrarily pushing the dose up.

• Pharmacology of Vasoactive Drugs in Neonates (Eugene Dempsey)

  • The Data Void: There is an extreme lack of pharmacokinetic (PK) and drug clearance studies in premature infants. We are heavily relying on adult extrapolation, which is complicated given the differences in volume distribution, immature enzyme pathways, and highly variable renal clearance. For instance, most of our dopamine data comes from small cohorts 30+ years ago, and there is virtually zero PK data on adrenaline in preterms.

  • The Rule of 5 Half-Lives: It takes 5 elimination half-lives to reach a steady-state concentration. For dobutamine, the half-life in preterms varies wildly (from 3 to 36 minutes). This means it can take anywhere from 15 minutes to 3 hours just to reach a steady state!

  • Clearance and Escalation Traps: Steady-state concentration is dictated by the infusion rate divided by drug clearance. Crucially, increasing the infusion rate does not shorten the time to reach the new steady state—it just sets a new target that will still take 5 half-lives to achieve.

• Antenatal Steroids and Pulmonary Hypertension (Gonzalo Solis-Garcia)

  • Elevated pulmonary pressures are common in extremely preterm infants during the first 72 hours.

  • Infants who received a complete course of antenatal steroids showed significantly lower (more normal) pulmonary pressures compared to those with incomplete courses.

• Cardiovascular Remodeling after Fetal Growth Restriction (Celina Brunsch)

  • In the first week of life, there was no significant difference in cardiac strain (left ventricular function) between preterm infants with FGR and those without FGR. Preterm birth itself may have a more dominant impact on early cardiac strain than the added factor of FGR, heavily influenced by the presence of a PDA.

  • However, FGR infants did show impaired cerebral autoregulation compared to their non-FGR preterm peers, a pattern that emerges strongly after the first three postnatal days, potentially linked to a prolonged brain-sparing effect.

Let’s keep the conversation going! How does your unit handle these hemodynamic challenges?

1. The PDA Dilemma: With the ongoing debate between active pharmacological closure and expectant management for extreme preterms, how has your unit's approach to the PDA evolved over the last five years?

2. The "Waiting Game" with Infusions: Given the extreme variability in clearance and the fact that it takes 5 half-lives (up to 3 hours for dobutamine!) to reach a steady state, how do you manage the urge to rapidly escalate doses at the bedside when the blood pressure isn't responding immediately?

Disclosure: This is an AI-assisted summary of the session, generated from a recording made by our team in attendance. We believe it is as accurate as our own notes would be, but please refer to the speakers’ original work before applying anything in clinical practice.